Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Drug Saf

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    June 2022
  1. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
    Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
    Drug Saf. 2022;45:685-698.
    PubMed     Abstract available


    May 2022
  2. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
    Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Drug Saf. 2022;45:535-548.
    PubMed     Abstract available


    April 2022
  3. KANT A, Jansen J, van Balveren L, van Hunsel F, et al
    Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Drug Saf. 2022;45:319-331.
    PubMed     Abstract available


    February 2022
  4. FERNER RE, Stevens RJ, Anton C, Aronson JK, et al
    Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
    Drug Saf. 2022;45:137-144.
    PubMed     Abstract available


    December 2021
  5. LUXI N, Giovanazzi A, Capuano A, Crisafulli S, et al
    COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
    Drug Saf. 2021;44:1247-1269.
    PubMed     Abstract available


    November 2021
  6. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
    Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
    Drug Saf. 2021;44:1125-1149.
    PubMed     Abstract available


  7. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
    Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Drug Saf. 2021;44:1209-1214.
    PubMed     Abstract available


    October 2021
  8. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
    Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
    PubMed     Abstract available


    September 2021
  9. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    PubMed     Abstract available


  10. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    PubMed     Abstract available


    June 2021
  11. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    PubMed     Abstract available


    April 2021
  12. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed    


  13. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    PubMed     Abstract available


    February 2021
  14. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    PubMed    


    January 2021
  15. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    PubMed     Abstract available


  16. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    PubMed    


    December 2020
  17. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    PubMed     Abstract available


  18. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available


  19. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available


  20. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available


    August 2020
  21. OSBORNE V, Davies M, Lane S, Evans A, et al
    Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:809-821.
    PubMed     Abstract available


  22. SULTANA J, Cutroneo PM, Crisafulli S, Puglisi G, et al
    Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Drug Saf. 2020;43:691-698.
    PubMed     Abstract available


  23. TUCCORI M, Convertino I, Ferraro S, Cappello E, et al
    The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
    Drug Saf. 2020;43:699-709.
    PubMed     Abstract available


    July 2020
  24. MOORE N, Carleton B, Blin P, Bosco-Levy P, et al
    Does Ibuprofen Worsen COVID-19?
    Drug Saf. 2020;43:611-614.
    PubMed    


  25. OLRY A, Meunier L, Delire B, Larrey D, et al
    Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Drug Saf. 2020;43:615-617.
    PubMed    


  26. MONTASTRUC JL, Toutain PL
    A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug Saf. 2020;43:657-660.
    PubMed     Abstract available


  27. DAVIES M, Osborne V, Lane S, Roy D, et al
    Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:645-656.
    PubMed     Abstract available


    June 2020
  28. CHANDLER RE, McCarthy D, Delumeau JC, Harrison-Woolrych M, et al
    The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.
    Drug Saf. 2020;43:511-512.
    PubMed    


  29. TRIFIRO G, Crisafulli S, Ando G, Racagni G, et al
    Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Drug Saf. 2020;43:507-509.
    PubMed    


    May 2020
  30. MOORE N
    Chloroquine for COVID-19 Infection.
    Drug Saf. 2020;43:393-394.
    PubMed    


    December 2019
  31. DOS SANTOS G, Nguyen BY, Damaso S, Godderis L, et al
    Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Drug Saf. 2019 Dec 28. pii: 10.1007/s40264-019-00893.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: